-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

955 Amot Inhibits Tumorigenesis of Diffuse Large B-Cell Lymphoma By Regulating DNA Damage Response

Program: Oral and Poster Abstracts
Session: 603. Oncogenes and Tumor Suppressors: Poster I
Hematology Disease Topics & Pathways:
Diseases, Non-Biological, Therapies, chemotherapy, B-Cell Lymphoma, Biological Processes, DNA damage, Lymphoid Malignancies
Saturday, December 5, 2020, 7:00 AM-3:30 PM

Tan Sang, PhD1,2,3*, Juan Yang, PhD1,2*, Jiarui Liu2,4*, Yang Han, MM1,5*, Ying Li, MD1,2*, Xiangxiang Zhou, MD1,2* and Xin Wang, MD, PhD1,5

1Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, China
2Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China
3Department of Hematology, Jinan Central Hospital affiliated to Shandong University, Jinan, Shandong, China
4Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China
5Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China

Background: Angiomotin (AMOT) was initially identified as a medium that binding to angiostatin and regulating angiogenesis or endothelial cell migration. Accumulating evidences support that AMOT is associated with tumor proliferation, apoptosis and invasion. However, the potential role and functional mechanism of AMOT in diffuse large B-cell lymphoma (DLBCL) have not been well-characterized. We hypothesized that AMOT could inhibit tumorigenesis and enhance chemosensitivity by regulating DNA damage response (DDR). In the current study, we evaluated the expression and function of AMOT in DLBCL tissues and cell lines. We also assessed the proliferation, cell cycle and apoptosis of DLBCL cells when treated with doxorubicin. The aim of this study is to investigate the functional significance of AMOT and its therapeutic potential in DLBCL.

Methods: Immunohistochemistry staining (IHC) for AMOT expression was performed on tissues of 52 newly diagnosed DLBCL and 25 reactive hyperplasia cases (controls). Peripheral blood mononuclear cells (PBMCs) were isolated from three healthy volunteers. Expression levels of AMOT mRNA and protein in DLBCL cells and PBMCs (controls) were detected by RT-PCR and western blot. Stable overexpressed cell lines (LV-AMOT) were generated by lentiviral infection. Effects of cell viability, cycle and apoptosis were assessed by cell counting kit-8 assay, propidium iodide and Annexin V-PE/7AAD staining, respectively. Moreover, we examined the effect of AMOT on the key protein of DDR by western blot.

Results: The percentage of AMOT-positive cells in DLBCL samples was statistically less than in reactive hyperplasia of lymph nodes tissues (Fig. 1A). The expression of AMOT was negatively associated with serum lactate dehydrogenase (LDH, P=0.023) and international prognostic index (IPI) score (P=0.017). Furthermore, Kaplan-Meier analysis indicated that the median survival of patients was significantly longer in AMOT-positive group than AMOT-negative group (Fig. 1B). DLBCL cells (LY1, LY8 and Val) exhibited remarkably lower mRNA as well as protein levels of AMOT compared to the control groups (Fig. 1C and D). AMOT-overexpression caused substantial growth suppression (Fig.1E) and increased proportion of cells in the G1 phase, with a concomitant decrease in the S phase of DLBCL cells (Fig. 1F). However, no significant change in the apoptosis rate after AMOT upregulation was observed.

The effect of AMOT on the activating phosphorylation of several key checkpoint proteins was examined by western blot assay. AMOT upregulation attenuated the activating phosphorylation of ATM(Ser1981), ATR (Ser428), Chk1 (Ser345), Chk2 (Thr68), and H2AX (Ser139) (Fig. 1G). However, the mRNA expression level of these genes did not change.

To investigate the effect of AMOT on the chemosensitivity of DLBCL cells, we incubated the DLBCL cells with doxorubicin for different concentrations or different time. The LV-AMOT group showed increased sensitivity to doxorubicin compared to the LV-Con group (Fig. 1H). Compared with the control, the LV-AMOT group showed an increased accumulation of cells in the G1 phase (Fig. 1I) and improved apoptosis rate (Fig. 1J). Western blotting showed that AMOT upregulation attenuated the activating phosphorylation of ATM (Ser1981)、ATR (Ser428)、Chk1 (Ser345)、Chk2 (Thr68) and H2AX (Ser139) after doxorubicin (160nM) treatment for 24 hours(Fig. 1K).

Conclusion: AMOT acts as a tumor suppressor via inhibition of the DDR, thus reducing the viability while increasing chemosensitivity in DLBCL. AMOT may be a potential target for DLBCL patients with doxorubicin resistance.

Disclosures: No relevant conflicts of interest to declare.

<< Previous Abstract | Next Abstract
*signifies non-member of ASH